Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
404.21
+12.57 (3.21%)
At close: Oct 1, 2025, 4:00 PM EDT
403.49
-0.72 (-0.18%)
After-hours: Oct 1, 2025, 7:47 PM EDT
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
9.11
Revenue / Employee
$1,871,934
Employees
6,100
Market Cap
103.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VRTX News
- 6 days ago - Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership - Seeking Alpha
- 6 days ago - Vertex Announces Key Advancements Across Kidney Portfolio - Business Wire
- 8 days ago - Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain - Business Wire
- 8 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - Business Wire
- 18 days ago - Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality - Seeking Alpha
- 20 days ago - Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis - Business Wire
- 22 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha